Bob Nelsen at #JPM23 (Adrien Villez for Endpoints News)
April 23, 2024 08:00 AM EDTUpdated 10:53 AM
People
Startups
AI

Why VC leg­end Bob Nelsen is mak­ing the biggest ini­tial bet of his 37-year ca­reer on Xaira

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

In the 37 years since co-found­ing ARCH Ven­ture Part­ners, Bob Nelsen has built a rep­u­ta­tion for plac­ing head-turn­ing bets on ideas that car­ry huge amounts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times